Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 10 January 2026 - 14 January 2026

Beyond Air (XAIR) stock whipsaws after NeuroNOS deal — premarket drop follows 150% rally

Beyond Air (XAIR) stock whipsaws after NeuroNOS deal — premarket drop follows 150% rally

NEW YORK, January 14, 2026, 05:10 (EST) — Premarket Shares of Beyond Air, Inc. plunged 16.4% to $1.83 in premarket action Wednesday, following a wild 150% surge that closed Tuesday at $2.19. The stock swung between $1.37 and $2.66 during Tuesday’s session, with volume skyrocketing to roughly 408.6 million shares—far above the three-month average of 6.76 million. (Investing) The swing…
14 January 2026
····
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

NEW YORK, Jan 13, 2026, 16:19 EST — After-hours Shares of Harmony Biosciences Holdings Inc (HRMY) slid 6.4% on Tuesday to close at $35.82, after trading as low as $34.69. The move comes as investors work through a pipeline reshuffle and a new revenue outlook that landed just as healthcare executives crowd into San Francisco for the annual J.P. Morgan…
13 January 2026
·····
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

New York, Jan 13, 2026, 13:22 (EST) — Regular session Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early afternoon trading. (TipRanks) The call hit in the middle of the J.P. Morgan Healthcare Conference week, when investors often press…
13 January 2026
·····
Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally

Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally

New York, Jan 13, 2026, 05:28 ET — Premarket Beam Therapeutics Inc (BEAM.O) slipped roughly 0.6% to $33.47 in premarket trading Tuesday, following a sharp 22.3% jump during Monday’s session. The shares climbed as high as $36.44 Monday and saw volume around 7.0 million shares. (StockAnalysis) The jump is significant as Beam aims to transform gene-editing science into a filing…
13 January 2026
·····
ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

New York, Jan 13, 2026, 05:42 (ET) — Premarket ImmunityBio shares were down 0.8% in premarket trading on Tuesday at $2.57, as of 5:00 a.m. ET. Around 13,000 shares had traded by that point, according to Public.com data. Premarket trading runs before the regular U.S. session opens at 9:30 a.m. ET and can be choppy. (Public) The biotech’s latest catalyst…
13 January 2026
···
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors digested the company’s new five-year strategy and 2026 revenue outlook, rolled out around the J.P. Morgan Healthcare Conference in San…
13 January 2026
·····
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

New York, Jan 12, 2026, 09:54 EST — Regular session Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a rare post-transplant cancer. The stock was volatile, swinging between $4.77 and $15.40 as investors reacted to the news, with volume…
12 January 2026
·····
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock closed at 340.80 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The deal underscores how big pharma continues to invest…
11 January 2026
·····
Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

New York, Jan 11, 2026, 08:01 EST — Market closed. Shares of Liquidia Corporation jumped 12.9% to close at $35.86 on Friday, following a strong sales surge for its inhaled treprostinil therapy, YUTREPIA. The stock traded between $29.41 and $38.07 throughout the day. This shift carries weight as Liquidia remains in the early phase of its commercial rollout. Investors want…
11 January 2026
·····
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

New York, January 11, 2026, 07:42 EST — Market closed CG Oncology shares jumped 29.26% on Friday, finishing at $54.20, setting a strong tone for Monday’s open. The boost came after the company announced it now anticipates Phase 3 PIVOT-006 topline results in the first half of 2026. (Poteau Daily News) The company said the quicker readout comes after enrollment…
11 January 2026
····
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

New York, January 10, 2026, 09:47 EST — Market closed Revolution Medicines shares jumped 10.7% to close at $118.64 on Friday, hitting a session high of $125.79 amid merger rumors. The Financial Times reported that Merck is negotiating a potential $28 billion to $32 billion acquisition of the biotech. (Financial Times) The timing matters. A deal with Revolution would give…
10 January 2026
····
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 (EST) — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to…
10 January 2026
······
1 2 3 4 5 … 12

Stock Market Today

  • Super Bowl Prediction Markets Sidestep Sports Betting Bans in California
    February 5, 2026, 7:44 AM EST. Prediction market platforms like Kalshi and Polymarket enable sports wagering in states banning traditional sportsbooks, including California. These platforms let users trade event contracts rather than place conventional bets, creating a legal gray area as they avoid acting as the 'house' while charging fees. Kalshi reported $161 million in Super Bowl market trading volume, a sixfold rise from last year. Critics question if these contracts amount to repackaged gambling, referencing California's century-old law prohibiting betting on sports. Industry advocates argue these markets are federally regulated financial exchanges distinct from traditional sportsbooks, allowing traders to buy and sell positions until outcomes settle. Legal experts suspect courts will allow this activity to continue for years amid regulatory uncertainty.
Go toTop